Diagnosing diastolic dysfunction using explainable advanced electrocardiography

Hayden McColl*1,2, Sabbab Chowdhury*1,3, Todd T Schlegel4,5, Maren Maanja4,
Kevin Yang1,3, Thomas Lindow1,6, Michelle Price7, Elias Fulthorp7, Sean Lal2,3,7,
Michele McGrady2,7, Rebecca Kozor1, Martin Ugander1,3,4

*Denotes equal contribution

1Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia
2Royal Prince Alfred Hospital, Sydney, Australia
3University of New South Wales, Sydney, Australia
4Department of Clinical Physiology, Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden
5Nicollier-Schlegel SARL, Trelex, Switzerland
6Clinical Physiology, Clinical Sciences, Lund University, Lund, Sweden
7Central Sydney Cardiology, Sydney, New South Wales

Corresponding Address:

Martin Ugander, MD, PhD
Professor of Cardiac Imaging, University of Sydney
Kolling Building, Level 12, Room 612017
Royal North Shore Hospital
St Leonards, Sydney NSW 2065
Australia
martin.ugander@gmail.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

BACKGROUND AND AIMS: Diastolic dysfunction of the left ventricle is a precursor to heart failure with preserved ejection fraction (HFpEF). Detection by electrocardiography (ECG) when asymptomatic (stage B heart failure) would be valuable. We hypothesised that an explainable advanced ECG (A-ECG) score derived from standard 12-lead ECG could accurately diagnose diastolic dysfunction.

METHODS: Included patients had undergone resting 12-lead ECG and echocardiography demonstrating normal systolic function, with at most mild valve disease, and either the presence (n=150) or absence (n=264) of grade II or III diastolic dysfunction. Stepwise multivariable logistic regression was used to generate an A-ECG score that was cross-validated using bootstrapping.

RESULTS: A 6-measure A-ECG score was able to identify diastolic dysfunction with an area under the receiver operating characteristics curve [95% confidence interval] of 0.91 [0.88-0.94], sensitivity 83 [76-91]%, specificity 87 [77-92]%, positive predictive value 78 [69-85]%, negative predictive value 90 [86-94]%, positive likelihood ratio 6.38 [3.30-11.38] and inverse negative likelihood ratio 5.12 [3.21-10.22].

CONCLUSIONS: Standard 12-lead ECG can be used to accurately identify diastolic dysfunction by echocardiography via A-ECG. This may have clinical utility for early identification of patients who may benefit from further cardiac assessment and risk factor management to prevent progression to symptomatic heart failure.
Introduction

Left ventricular (LV) diastolic dysfunction describes abnormalities in myocardial relaxation, compliance, and filling, thereby increasing the risk of developing heart failure with preserved ejection fraction (HFpEF)\(^1\).\(^2\). Diastolic dysfunction may be initially asymptomatic (stage 2 heart failure) before progressing to symptomatic HFpEF (stage C and D), and may be present for many years before manifesting as overt heart failure\(^3\).\(^4\). Aggressive management of cardiovascular risk factors including hypertension, diabetes and obesity has been shown to prevent or reduce disease progression\(^5\). Due to diastolic dysfunction commonly being asymptomatic before manifesting as HFpEF, earlier identification to better enable risk factor modification is desirable.

Diastolic dysfunction is most commonly assessed using transthoracic echocardiography. However, echocardiographic screening is not feasible on a population scale due to resource-related constraints\(^6\). As such, a low-cost screening method for diastolic dysfunction would be clinically valuable.

Attempts to use variations of the electrocardiogram (ECG) as a screening tool for diastolic dysfunction have shown promise. However, previous studies have relied heavily upon clinical data beyond the ECG or included methods that are difficult to implement on a large scale due to requirements for dedicated hardware that may not be widely available\(^7\).\(^8\).

Advanced electrocardiography (A-ECG) is a term describing the application of multivariable statistics to a large number of measures obtained from a combination of analysis methods applied to the standard resting 12-lead ECG\(^9\).\(^10\). Notably, A-ECG analysis can be performed on the raw digital ECG data recordings stored by any modern ECG vendor. A-ECG analysis on standard 10-sec ECGs enables improved diagnostic performance by incorporating not only conventional ECG measurements such as waveform amplitudes, axes and durations, but also measures of derived three-dimensional vectorcardiography (VCG) and...
waveform complexity via singular value decomposition. A-E CG has been able to discriminate between health and disease in several conditions such as coronary artery disease, cardiomyopathy, LV hypertrophy and LV systolic dysfunction, with notably higher diagnostic accuracy compared to conventional ECG. However, there have not yet been studies examining the utility of A-E CG in the diagnosis and screening of diastolic dysfunction. A-E CG may have use for screening at-risk, asymptomatic patients for diastolic dysfunction in the setting of constrained resources. Such patients might benefit from further investigation and aggressive risk factor management to prevent progression of disease to HFpEF and reduce its globally increasing burden.

Therefore, the aim of this study was to test the utility of an A-E CG scoring system for the diagnosis of diastolic dysfunction derived from a resting 12-lead ECG. We hypothesised that combined measures of A-E CG derived from the standard resting 12-lead ECG could be used to accurately identify the presence of diastolic dysfunction.

Methods

Study Design
This was a single-centre retrospective study of A-E CG in patients with diastolic dysfunction versus those with normal diastolic function as determined by transthoracic echocardiography (TTE). The study included patients who were referred for assessment at a large academic outpatient cardiology practice between January, 2018 and March, 2022. The study received ethics approval from the Sydney Local Health District Ethics Board (X19-0286 & 2019/ETH12064) as well as the respective human research ethics committee of the participating centre, with a retrospective waiver of informed consent.

Study inclusion criteria were age >50 years, sinus rhythm, left ventricular ejection fraction (LVEF) ≥55% and a recorded 12-lead ECG within 1 month of echocardiography.
Patients were excluded if they had moderate or greater valvular disease, LVEF <55%, hypertrophic cardiomyopathy, previous valvular replacement, coronary artery bypass surgery, or any other cardiac procedures that had required entering the pericardium. Exclusion criteria were ECG abnormalities that would limit A-ECG analysis such as atrial arrhythmias, predominant ventricular ectopic beats or QRS duration >110ms.

Echocardiographic examinations were evaluated and patients classified as having either normal or abnormal diastolic function. Abnormal diastolic dysfunction was defined as meeting criteria for either grade 2 or 3 diastolic dysfunction per the 2016 American Society of Echocardiography (ASE) assessment of diastolic dysfunction guidelines. Normal diastolic function was defined as the absence of any required criteria. The patient inclusion flowchart is presented in detail in Figure 1.

Advanced electrocardiography analysis

All ECG recordings were performed by a commercial ECG system that acquired a resting 12-lead ECG of 10 second duration (Mortara Instruments Inc., USA). A-ECG analysis and its extensive methods have been detailed previously. In brief, conventional ECG parameters, including all major waveform intervals, axes, and voltages were derived automatically from the ECG recording software. A-ECG parameters were obtained after signal averaging the full ECG recordings using the in-house developed software. Derived -VCG measures were obtained from the 12-lead ECG using Kors’ regression transformation. QRS and T wave complexity was measured after signal averaging by using singular value decomposition.

An electrocardiographic heart age can also be estimated from 10-second 12-lead ECG recordings through use of A-ECG. A person’s heart age and related heart age gap (the AECG heart age minus chronological age) reflect a person’s cardiovascular risk profile based on a range of ECG changes, expressed in units of years of healthy human ageing. AECG
Heart age and heart age gap were therefore calculated from the ECG for all patients in our cohort using a previously described A-ECG method\(^9\). Moreover, the likelihood of having left ventricular systolic dysfunction was also determined from the resting 12-lead ECG by using previously described A-ECG methods\(^9\).

**Statistical Analysis**

Statistical analyses including feature selection procedures were conducted using R version 4.2.0 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria) with packages dplyr for data transformation and ggplot2 for data visualisation, and SAS JMP version 11.0 (Cary, NC, USA)\(^{17,18}\). Continuous variables are presented as mean ± standard deviation or median [interquartile range], as appropriate. Standard stepwise logistic regression was used to derive multivariable A-ECG scores for assessing diastolic dysfunction. The area under the receiver operating characteristics curve (AUC) for the A-ECG scores was calculated and the entire data set subsequently bootstrapped 2000 times to determine cross-validated diagnostic accuracy and obtain 95% confidence intervals (CI)\(^{13}\). The Youden index was used to optimise cut-offs for the specificity and sensitivity for each score to detect diastolic dysfunction\(^{13,19}\). The A-ECG score was then used to estimate the probability of any subject in the study cohort having diastolic dysfunction, with cut-off predicted probability of >0.5. The score calculated the likelihood of having diastolic dysfunction from the logistic regression as:

\[
\text{Likelihood of diastolic dysfunction} = \frac{1}{1 + e^{-(\text{coefficients} \times \text{parameters} + \text{adjusted constant})}} \times 100
\]

A Student’s \(t\) test was used to compare the mean values of A-ECG measures between cohorts. A p-value <0.05 was considered statistically significant.
Results

Study Population

The population considered consisted of 414 patients with baseline characteristics presented in Table 1. There were 264 patients with normal diastolic function and 150 with diastolic dysfunction (133 with grade 2 and 17 with grade 3 diastolic dysfunction). In the normal diastolic function group, 45% were males and mean age was 62.1±9.1 years. In the diastolic dysfunction group, 35% were males and mean age was 76.7±9.4 years. For purposes of subgroup analysis, the full cohort was also divided into an age-matched sub-cohort consisting of normal diastolic function (n=100) and diastolic dysfunction (n=100). The mean ages of the age-matched cohorts did not differ (71.8±4.8 vs 72.0±7.7 years, p=0.89). The study excluded patients with LVEF <55%. A-ECG scores previously validated for the detection of reduced LVEF were also applied to this cohort, confirming a low likelihood of left ventricular systolic dysfunction for both the control and diastolic dysfunction cohorts (7 [3–18] % and 13 [4–33] %, respectively), where a probability of >50% was considered a high likelihood.

6-measure A-ECG score including age

Standard feature selection based on stepwise logistic regression were used for constructing an A-ECG score for diastolic dysfunction. The optimal score ultimately contained six measures, with the two measures contributing most strongly to the score being age and the Cornell voltage product. The full list of measures is detailed in Table 2. This optimal 6-measure score provided excellent discrimination (AUC 0.91 [0.88-0.94]), see Table 3. Figure 2 shows representative ECGs from two patients with high and low probabilities for diastolic dysfunction, respectively, by the A-ECG score. Table 4 compares the A-ECG measures between the normal and diastolic dysfunction cohort.

6-measure A-ECG score without P-wave components
A 6-measure A-ECG score that did not include any P-wave components was also created and displayed a negligibly lower diagnostic performance for identifying diastolic dysfunction (AUC 0.91 [0.87-0.93]). The details of this score are also detailed in Table 3.

**Age-independent analysis**

To better understand the effect of age on the 6-measure A-ECG scores, another, less optimal score was also ultimately created using purely A-ECG-derived variables, excluding age. Ten rather than six measures were necessary for this score to best compensate for the lack of inclusion of the most powerful measure of age. This 10-measure score ultimately included four A-ECG measures from the 6-measure score, and six additional A-ECG measures. The measures included in this score, and its diagnostic performance in both the full cohort and the age-matched sub-cohort, are presented in Tables 2 and 3, respectively. Figure 3 illustrates the comparative receiver operating characteristics curves for the performance of the optimal 6-measure score in the full cohort, and the 10-measure score in both the full and age-matched cohorts, respectively. The 10-measure score had similar diagnostic performance to age in isolation when applied to the full cohort (AUC: 0.85 [0.81-0.89] vs 0.87 [0.82-0.90], respectively). The full diagnostic performance is detailed in Table 3.

**Heart Age**

Heart age and heart age gap in the full and age-matched cohorts, respectively, are summarised in Figure 4. Compared to the group without diastolic dysfunction, the heart age gap was greater in the diastolic dysfunction group in both the full cohort (14.5±10.4 vs 10.7±8.5 years, p<0.001) and the age-matched cohort (14.8±10.1 vs 9.9±9.4 years, p=0.001). Heart age gap alone demonstrated a modest predictive ability in identifying diastolic dysfunction when applied to our whole cohort (AUC 0.62 [0.56–0.68]). A weak correlation was demonstrated between heart age gap and our optimal 6-measure A-ECG score for diastolic dysfunction (R^2=0.05, p<0.001).
Discussion

This study is the first to investigate the utility of A-ECG as a potential screening tool for diastolic dysfunction. Its major finding is that a 6-measure A-ECG score derived from a routine 12-lead ECG can identify diastolic dysfunction with clinically acceptable diagnostic performance. In addition to its diagnostic accuracy, our reported likelihood ratios demonstrate the utility of A-ECG analysis on an individual level independent of the prevalence of diastolic dysfunction in the population being studied. We have additionally chosen to report the inverse negative likelihood ratio as it helps illustrate the utility of a negative result following A-ECG testing expressed in a magnitude comparable to the positive likelihood ratio. For example, the optimal 6-measure score’s inverse negative likelihood ratio of 5.12 suggests that following a negative A-ECG result, a patient is 5.12 times less likely to be diagnosed with diastolic dysfunction on TTE. Overall, these results suggest that A-ECG shows promise as a low-cost screening tool for identifying diastolic dysfunction and as a potential early-prevention measure for HFpEF.

Validity and feasibility of A-ECG analyses

When considering our results, it’s important to consider the validity and feasibility of A-ECG as a technique for assessing disease. The introduction of the ECG in 1902 provided, for the first time, objective information about the electrical activity and function of the heart that could subsequently be used to diagnose a number of cardiac pathologies such as atrial fibrillation and myocardial infarction. However, it was only in the 1960s that a multivariable approach to the conventional ECG was applied to improve diagnostic detection of diseases such as LV hypertrophy and prior myocardial infarction. A-ECG is an extension of this arc of development, and is an emerging technology able to extract sufficient information from a standard resting 12-lead ECGs for the detection of a large range of cardiac pathologies. It has been shown to improve diagnostic accuracy when compared to
conventional ECG in coronary artery disease, cardiomyopathies, LV hypertrophy and LV systolic dysfunction\textsuperscript{10, 13, 14}.

To date, there is no widely accepted ECG-based method for detecting diastolic dysfunction. A machine learning model using clinical and ECG variables has shown potential to detect diastolic dysfunction with an AUC of 0.80 in an external test cohort\textsuperscript{7}. However, that model relied on inclusion of a range of information including clinical co-morbidities such as hypertension and dyslipidaemia that may limit its applicability as a screening tool wherever such information is not readily available. A single-lead ECG recorded with specialised dedicated hardware and sampling rate far exceeding routine clinical ECG for 3 minutes has also been able to achieve high diagnostic accuracy for detecting diastolic dysfunction\textsuperscript{8}.

However, a major barrier for its widespread use as a routine screening tool on large populations is the need for dedicated equipment. By comparison, A-ECG analysis can be performed on a digital raw data file from a standard, 10-second, 12-lead ECG recorded using existing standard-fidelity ECG devices\textsuperscript{10}.

The Cornell product was the single best performing A-ECG measure for the prediction of diastolic dysfunction. This is consistent with prior research which suggests that an increased Cornell product could be used to help diagnose diastolic dysfunction and was a marker of poor prognosis\textsuperscript{25}. Similarly, QTc prolongation was a significant predictor of diastolic dysfunction in our cohort, which is in keeping with prior research. This is believed to be related to the close temporal relationship between QT interval and the diastolic period of the cardiac cycle\textsuperscript{26}.

As such, the current study shows that the use of A-ECG techniques for detecting diastolic dysfunction achieves excellent diagnostic performance with methods that are economically and logistically feasible for widespread use. Furthermore, A-ECG can be performed rapidly and inexpensively using a standard 12-lead resting ECG while at the same
time also diagnosing or screening for other pathologies. Moreover, it’s likely that many
patients at risk of having or developing diastolic dysfunction would have pre-existing resting
12-lead ECGs from the past for convenient retrospective analysis.

Age and diastolic dysfunction

Age and sex were the only non-ECG measures considered in the multivariable
analysis, both comprising readily available information at the time of ECG data collection that
do not rely upon access to laboratory or other detailed clinical information or history. While
sex was not retained in the final model, age was the measure with the highest magnitude of
contribution to the multivariable logistic regression for the optimal score (Table 2).

This is consistent with our current understanding of the pathogenesis of diastolic dysfunction
and HFpEF. Similarly, the mean age of patients in our diastolic dysfunction cohort was higher
than that in our normal diastolic function control group, albeit with sizable overlap (77±9 vs
62±9 years). For reference the AUC of age in isolation was 0.87 [0.82-0.90]. The addition of
A-ECG measures to the 6-measure score further increased the AUC to 0.91[0.88-0.94], p
<0.001). A comparison performed by deriving a 10-measure score consisting of purely A-
ECG parameters while excluding age showed that A-ECG components provided significant
diagnostic information beyond age alone. A 10-measure score with only A-ECG measures
and without age achieved very good diagnostic performance in the full cohort. Overall, it had
a slightly lower AUC compared to the optimal 6-measure score (0.85 vs. 0.91) (Figure 3).
Notably, 4 A-ECG measures from the optimal 6-measure score were also retained within the
10-measure score, underscoring the general robustness of the A-ECG measures in the 6-
measure score. Age-related ECG changes are well known, including prolongation of P-wave
and QT intervals11. Therefore, it was important to determine whether or not the performance
of the 10-measure score is driven by the ability to predict age as opposed to diastolic
dysfunction per se. As such, the performance of the 10-measure score was evaluated in an age-matched sub-cohort to ensure it was identifying diastolic dysfunction as opposed to advanced age. The preserved diagnostic accuracy of the 10-measure score in the age-matched cohort (AUC 0.83) confirms that the A-ECG measures in this score associate with diastolic dysfunction and not just age alone. Taken together, the results of these additional analyses underscore that the 6-measure score can be used to accurately diagnose diastolic dysfunction.

Heart age gap was increased in patients with diastolic dysfunction in both the full and age-matched cohorts. This also indicates that A-ECG analysis can detect ECG changes both beyond age and independent of age, which differ between cohorts. It is worth noting that while patients without diastolic dysfunction had a lower heart age gap than those with diastolic dysfunction, the heart age gap was still elevated to a level (approximately +10 years) that was on average near the upper limit of normal for previously described, low-risk healthy volunteers (approximately +12 years)\textsuperscript{10}. This likely reflects the greater burden of cardiovascular risk factors and co-morbidities in our control group of patients referred to an outpatient cardiology clinic.

**Practical applications of A-ECG scores**

In the future, A-ECG may have application in a range of different clinical settings, in particular for primary care physicians where this novel information may allow for more accurate risk stratification for cardiac disease and assist in identifying only those patients who might most benefit from further cardiac imaging. In addition, the low skill and cost required to perform this analysis could provide significant value in population-based settings wherein relatively technically complex and expensive methods such as echocardiography might not be feasible. Another beneficial aspect of A-ECG is that it can simultaneously provide probability scores for a wide range of cardiac disease. Upon knowing the results of a transparently explainable numeric probability score available at the time of consultation, physicians may be better equipped to engage with patients regarding preventative therapy and lifestyle changes.
to reduce the risk of developing cardiovascular disease. Diastolic dysfunction is under-
diagnosed and a precursor to clinically overt HFpEF, the leading cause of heart failure. As
such, a low-resource screening tool for the diagnosis of diastolic dysfunction would be
particularly valuable to aid early identification of individuals who might benefit from further
cardiac assessment and risk factor modification to prevent or delay the development of
HFpEF. Additional, fully prospective follow-on studies using the proposed optimal A-ECG
score are therefore justified.

**Limitations**

The database used for this study had limited demographic information on patients, including a
lack of information on the prevalence of cardiovascular risk factors such as diabetes and
hypertension. Given that the control group was recruited from patients referred for outpatient
cardiac assessment, it’s also likely that this population contains a higher prevalence of cardiac
co-morbidities than what would be expected from asymptomatic, healthy controls. It is also
likely that even-age matched healthy controls would display an increased likelihood of
diastolic dysfunction due to normal healthy ageing. Consequently, there is a potential that the
reported accuracy of A-ECG analysis is underestimated and the use of fully asymptomatic
healthy controls as a normal cohort would further increase the strength of our predictive
model. However, our methodology and the wide inclusion criteria for both groups are closely
reflective of real-world practice faced by clinicians who may use this technology.

Additionally, our data were collected from a single outpatient cardiology practice. As such the
score may not be as generalisable to populations which differ greatly from our cohort.

The utility of the score might also be limited in patients who fall outside of our study
inclusion criteria, in particular patients younger than 50 years of age. However, it’s worth
noting that younger patients are less likely to be a target population for screening for diastolic
dysfunction. Furthermore, only patients in sinus rhythm and without significant conduction
disease were included in the study. Patients with atrial arrhythmia and/or ventricular
conduction disease, both prevalent in patients with diastolic dysfunction and heart failure, could therefore not currently be screened using our optimal A-ECG score. It would therefore be beneficial to develop additional, dedicated scores for patients with atrial fibrillation or advanced conduction disease in the future. Whilst this study did not include any patients in atrial fibrillation or flutter, our 6-measure score that excluded all measures from the P-wave also demonstrated excellent diagnostic accuracy (AUC 0.91 [0.87-0.93]). Whether this alternative score might therefore have diagnostic utility in patients with atrial arrhythmias remains to be ascertained. Finally, this was a single-center study, and both cross-validation and internal validation testing with an age-matched sub-cohort were used. The use of a separate, external validation cohort from a different center would help provide further confidence in the generalisability of our findings.

Conclusions

A 6-measure score derived from A-ECG analysis of the conventional resting 12-lead ECG is able to detect diastolic dysfunction with high diagnostic accuracy. A-ECG shows potential as a screening tool for diastolic dysfunction, to potentially reduce the number of unnecessary echocardiographic examinations while facilitating early management of cardiovascular risk factors to help mitigate progression to HFpEF.

Disclosures

TTS is owner and founder of Nicollier-Schlegel SARL, which performs ECG interpretation consultancy using software that can quantify the advanced ECG measures used in the current study. TTS and MU are founders of Advanced ECG Systems, a company that is developing commercial applications of advanced ECG technology used in the current study. RK has a financial interest in Advanced ECG Systems through being married to MU.
References


### 2. Table 1. Patient characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Normal diastolic function</th>
<th>Diastolic dysfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients, n (%)</td>
<td>264 (64)</td>
<td>150 (36)</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>119 (45)</td>
<td>53 (35)</td>
</tr>
<tr>
<td>Age, years</td>
<td>62.1 ± 9.1</td>
<td>76.7 ± 9.4</td>
</tr>
<tr>
<td>Body surface area, m²</td>
<td>1.9 ± 0.2</td>
<td>1.8 ± 0.2</td>
</tr>
</tbody>
</table>

**Echocardiographic data**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Normal diastolic function</th>
<th>Diastolic dysfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td>LA volume index, ml/m²</td>
<td>29.8 ± 8.0</td>
<td>45.2 ± 10.5</td>
</tr>
<tr>
<td>LV septal wall thickness, mm</td>
<td>9.4 ± 1.8</td>
<td>11.3 ± 2.1</td>
</tr>
<tr>
<td>LV posterior wall thickness, mm</td>
<td>9.1 ± 1.0</td>
<td>10.0 ± 2.2</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>1.1 ± 0.4</td>
<td>1.1 ± 0.5</td>
</tr>
<tr>
<td>Average E/e’ ratio</td>
<td>8.3 ± 2.3</td>
<td>14.9 ± 4.4</td>
</tr>
<tr>
<td>TR velocity, m/s</td>
<td>2.3 ± 0.3</td>
<td>2.8 ± 0.5</td>
</tr>
<tr>
<td>Peak E-Wave velocity, cm/s</td>
<td>71 ± 17</td>
<td>88 ± 21</td>
</tr>
<tr>
<td>Average e’ velocity, cm/s</td>
<td>9.1 ± 2.6</td>
<td>6.3 ± 2.0</td>
</tr>
<tr>
<td>Septal e’ velocity, cm/s</td>
<td>10.6 ± 3.2</td>
<td>7.1 ± 2.5</td>
</tr>
<tr>
<td>Lateral e’ velocity, cm/s</td>
<td>7.6 ± 2.2</td>
<td>5.7 ± 1.8</td>
</tr>
</tbody>
</table>

All data reported as mean ± standard deviation. All other values represent total number (percent) of affected individuals. Abbreviations: BSA = body surface area; E/e’ = E to septal e’ velocity ratio; LA = left atrial; LV = left ventricular; TR = Tricuspid regurgitation.
Table 2. A-ECG measures involved in the respective scores.

<table>
<thead>
<tr>
<th>ECG measures</th>
<th>6-measure A-ECG score</th>
<th>6-measure A-ECG score (without any P-wave components)</th>
<th>10-measure A-ECG score without age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Coefficient Estimate</td>
<td>Chi-square</td>
<td>p-value</td>
</tr>
<tr>
<td>Age, years</td>
<td>0.171924</td>
<td>90.1</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Cornell Product, mV*ms</td>
<td>0.013901</td>
<td>19.8</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>P’ amplitude in lead V3, uV</td>
<td>-0.079075</td>
<td>10.5</td>
<td>0.001</td>
</tr>
<tr>
<td>Change of the QRS azimuth between five eighths to four eighths of the duration of the spatial QRS loop, degrees</td>
<td>0.015809</td>
<td>9.6</td>
<td>0.002</td>
</tr>
<tr>
<td>Corrected QT interval, ms</td>
<td>0.017390</td>
<td>9.2</td>
<td>0.002</td>
</tr>
<tr>
<td>Minimum azimuth of the spatial QRS loop, sine radians</td>
<td>3.5621222</td>
<td>5.4</td>
<td>0.02</td>
</tr>
<tr>
<td>Net area subtended by the T wave in derived lead X, uV*ms</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>The slope of the ST segment in lead III, uV/s</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cornell Voltage, mV</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>P’ amplitude in lead aVR, uV</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Magnitude of the ST-T segment six eighths of the way through the spatial ST-T loop, uV</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5th singular value of the T wave, log uV</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>R duration in lead I, ms</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Intercept</td>
<td>-17.803501</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Table 3. Accuracies and Predictive Values of all calculated A-ECG Scores in the full study cohort and age-matched sub-cohort.

<table>
<thead>
<tr>
<th>A-ECG score</th>
<th>Cohort for testing</th>
<th>AUC</th>
<th>Sensitivity(%)</th>
<th>Specificity(%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
<th>PLR</th>
<th>INLR</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 measures including age</td>
<td>Full</td>
<td>0.91 [0.88-0.94]</td>
<td>83 [76-91]</td>
<td>87 [77-92]</td>
<td>78 [69-85]</td>
<td>90 [86-94]</td>
<td>6.38 [3.30-11.38]</td>
<td>5.12 [3.21-10.22]</td>
</tr>
<tr>
<td>6 measures including age, but without P-wave components</td>
<td>Full</td>
<td>0.91 [0.87-0.93]</td>
<td>81 [71-91]</td>
<td>87 [77-93]</td>
<td>78 [67-86]</td>
<td>89 [85-94]</td>
<td>6.23 [3.09-13.00]</td>
<td>4.58 [2.66-10.33]</td>
</tr>
<tr>
<td>10 measures without age</td>
<td>Full</td>
<td>0.85 [0.81-0.89]</td>
<td>73 [61-93]</td>
<td>83 [61-94]</td>
<td>72 [57-84]</td>
<td>85 [80-94]</td>
<td>4.29 [1.56-15.50]</td>
<td>3.07 [1.56-13.43]</td>
</tr>
<tr>
<td>10 measures without age</td>
<td>Age-matched</td>
<td>0.83 [0.77-0.88]</td>
<td>72 [56-86]</td>
<td>84 [68-94]</td>
<td>82 [71-92]</td>
<td>75 [67-84]</td>
<td>4.50 [1.75-14.33]</td>
<td>3.00 [1.55-6.71]</td>
</tr>
<tr>
<td>Age alone</td>
<td>Full</td>
<td>0.87 [0.82-0.90]</td>
<td>83 [68-91]</td>
<td>78 [69-90]</td>
<td>68 [61-80]</td>
<td>89 [83-93]</td>
<td>3.77 [2.19-9.10]</td>
<td>4.59 [2.16-10.00]</td>
</tr>
</tbody>
</table>

Full cohort (n=414), normal diastolic function (n=264) and diastolic dysfunction (n=150). Age-matched cohort (n=200), normal diastolic function (n=100) and diastolic dysfunction (n=100). Abbreviations: AUC = Area under curve; PPV = Positive predictive value; NPV = Negative predictive value; PLR = Positive likelihood ratio; INLR = Inverse of the negative likelihood ratio. Bracketed numbers are 95% confidence intervals derived from the bootstrap-related cross-validation procedure.
Table 4. Comparison of A-ECG measures and age between patients with normal diastolic function and diastolic dysfunction (6 measure Score including P wave components).

<table>
<thead>
<tr>
<th>Measure</th>
<th>Normal</th>
<th>Diastolic Dysfunction</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>62.1 ± 9.1</td>
<td>76.7 ± 9.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cornell Product, mV*ms</td>
<td>112 ± 46</td>
<td>141 ± 63</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>P’ amplitude in lead V3, uV</td>
<td>-0.21 ± 3.5</td>
<td>-5.7 ± 19.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Change of the QRS azimuth between five eighths to four eighths of the duration of the spatial QRS loop, degrees</td>
<td>-45.5 ± 25</td>
<td>-25.5 ± 40.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Corrected QT interval, ms</td>
<td>422 ± 28</td>
<td>433 ± 27</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Minimum azimuth of the spatial QRS loop, sine radians</td>
<td>-0.95 ± 0.09</td>
<td>-0.93 ± 0.16</td>
<td>0.03</td>
</tr>
</tbody>
</table>
Figure 1. Flowchart describing study inclusion and exclusion criteria. The selection criteria included patients referred for assessment at a large academic outpatient cardiology practice. The inclusion criteria included age >50, sinus rhythm, LVEF >55% and a recorded 12-lead ECG within 1 month of TTE. Patients were excluded if they had moderate or greater valvular disease, LVEF <55%, hypertrophic cardiomyopathy, valvular replacement, coronary bypass surgery, or any other cardiac procedures that required entering the pericardium. ECG abnormalities that would limit A-ECG analysis such as atrial arrhythmias, predominant ventricular ectopic beats and QRS duration >110ms were also excluded. Abbreviations: LVEF = Left ventricular ejection fraction; TTE = Transthoracic echocardiography.
Figure 2. Comparison of A-ECG results from the 12-lead ECGs of two representative patients. Patient A has normal diastolic function with a corresponding low likelihood for diastolic dysfunction (10%) by A-ECG scoring. Patient B has diagnosed diastolic dysfunction with a high likelihood for diastolic dysfunction (98%) by A-ECG scoring.
Figure 3. Comparisons of diagnostic performance for the 6-measure score in the full cohort, and the 10-measure score without age in the full and the age-matched cohort, respectively.
Figure 4: Heart age calculations in the full study cohort and age-matched sub-cohort.

Heart age gap is defined as A-ECG heart age minus chronologic age. Full cohort (n=414), normal diastolic function (n=264) and diastolic dysfunction (n=150). Age-matched cohort (n=200), normal diastolic function (n=100) and diastolic dysfunction (n=100).